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Abstract
Background: Screening with combined cytologic and HPV testing has led to the highest number
of excessive colposcopic referrals due to high false positive rates of the current HPV testing in the
USA. How best to capitalize on the enhanced sensitivity of HPV DNA testing while minimizing false-
positive results from its lower specificity is an important task for the clinical pathologists.
Methods: The HPV L1 gene DNA in liquid-based Pap cytology specimens was initially amplified by
the degenerate MY09/MY11 PCR primers and then re-amplified by the nested GP5+/GP6+
primers, or the heminested GP6/MY11, heminested GP5/MY09 primers or their modified
equivalent without sample purification or DNA extraction. The nested PCR products were used
for direct automated DNA sequencing. A 34- to 50-base sequence including the GP5+ priming site
was selected as the signature sequence for routine genotyping by online BLAST sequence alignment
algorithms.
Results: Of 3,222 specimens, 352 were found to contain HPV DNA, with 92% of the positive
samples infected by only 1 of the 35 HPV genotypes detected and 8% by more than 1 HPV
genotype. The most common genotype was HPV-16 (68 isolates), followed by HPV-52 (25 isolates).
More than half (53.7%) of the total number of HPV isolates relied on a nested PCR for detection
although the majority of HPV-16, -18, -31, -33 -35 and -58 isolates were detected by a single MY09/
MY11 PCR. Alignment of a 34-base sequence downstream of the GP5+ site failed to distinguish
some isolates of HPV-16, -31 and -33. Novel variants of HPV with less than "100% identities"
signature sequence match with those stored in the Genbank database were also detected by
signature DNA sequencing in this rural and suburban population of the United States.
Conclusion: Laboratory staff must be familiar with the limitations of the consensus PCR primers,
the locations of the signature sequence in the L1 gene for some HPV genotypes, and HPV genotype
sequence variants in order to perform accurate HPV genotyping.
Background
In the United States, approximately 20 million people are
currently infected with human papillomavirus (HPV) [1],
and 11,070 women are expected to be diagnosed with cer-
vical cancer in 2008 [2]. To further reduce the cancer risk,
testing high-risk HPV DNA in liquid-based cervicovaginal
Pap cytology specimens has been recommended in the
practice guidelines to direct clinical management of indi-
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vidual patients with a cytologic classification of atypical
squamous cells of undetermined significance (ASCUS) [3-
5]. Using the histological grade of CIN3/2 in the subse-
quent colposcopic biopsy as the end point for evaluation,
the sensitivity of the commercially available high-risk hc2
HPV assay (Digene, Gaithersburg, MD) is reported to be
50–75% [6,7], and its specificity 15–71% [6,8,9], depend-
ing on the age of the patients, the patient population and
the Pap cytology used in combination for triage. A recent
comprehensive analysis has confirmed that screening
with combined cytologic and HPV testing, regardless of
patient age, leads to the highest number of excessive col-
poscopic referrals due to high false positive rates of the
current HPV testing. According to this analysis, more than
95% of referrals to colposcopy for diagnostic workup are
false positive and/or potentially excessive. How best to
capitalize on the enhanced sensitivity of HPV DNA testing
while minimizing false-positive results from its lower spe-
cificity is an important question to be addressed in
upcoming screening guidelines [10].
In part due to the lack of a commercial type-specific HPV
test, about 19% of the clinical laboratories surveyed in
2006 by the College of American Pathologists (CAP)
relied on using a laboratory-developed test for HPV assay
[11]. The CAP has advised that rigorous validation is
required for offering a non-FDA-approved HPV test in cer-
tified high-complexity testing laboratories under CLIA 88
[12,13]. A 92% CIN 3 detection rate has been proposed as
the clinical sensitivity along with an 85% CIN 3 confirma-
tion as the clinical specificity for validation of all HPV
assays [14]. However, the results were largely disappoint-
ing when attempts were made to use a yardstick based on
interpretative human observations, such as the CIN grad-
ing, to validate the sensitivity and specificity of a molecu-
lar virology test [6-9] which is governed by the law of
physics, or vice versa [15].
Significant differences were noted in the detection of HPV
infection and individual genotypes when different probe
hybridization methods were used to test the same group
of specimens [16]. The SPF10-line probe assay (LiPA;
DDL Diagnostic Laboratory; Voorburg/The Netherlands)
detected more HPV-31 than HPV-16 while the line blot
assay (LBA; Roche Molecular Systems, Pleasanton, CA)
detected more HPV-16 than HPV-31 in the same samples,
as reported by two independent groups of authors
[16,17]. In addition, the LBA detected significantly more
HPV-42, HPV-56 and HPV-59 whereas the LiPA detected
more HPV-52 when these two hybridization methods
were compared in parallel studies [17]. These discrepan-
cies in HPV genotypes found in the same group of sam-
ples suggest that some HPV variants might have been
identified as different genotypes by different probe
hybridization methods. The US Food and Drug Adminis-
tration (FDA) has concluded "Complex probe cocktails may
crossreact and/or compete with one another. There is currently
no standardized clinical panel of representative HPV samples
available against which specific probe combinations can be
evaluated for clinical effectiveness." [18]
By definition, a genotype of HPV differs in the L1 gene
DNA sequence by at least 10% from every other known
HPV type. HPV subtypes are those having DNA sequence
similarities between 90% and 98% with a prototype in its
L1 gene; HPV variants are those having a DNA sequence
identity of over 98% of a prototype [19]. To sequence the
entire L1 gene (ca. 1.6 kb) for genotype determination of
the HPV DNA detected in each and every positive clinical
specimen is cost-prohibitive. However, it is possible to
analyze a hypervariable DNA segment of the L1 gene and
compare its sequence with those stored in the GenBank
database for genotyping [20-25]. Several institutes have
sequenced a 150 bp PCR amplicon defined by the GP5+/
GP6+ consensus primers for accurate genotyping
[20,22,23]. For routine practice, a sequence of 34 bases
downstream of the GP5 binding site has been proposed
for accurate genotyping of all clinically relevant anogeni-
tal HPV variants [20]. This study was designed to further
explore the possibility of using this method of HPV geno-
typing for routine application in a clinical laboratory to
improve the specificity of the current HPV testing and its
potential pitfalls.
Methods
The purified full-length plasmid DNAs of HPV types -6B,
-11, -16, and -18 purchased from American Type Culture
Collection (ATCC) were used as HPV DNA standards. The
nested PCR products generated of these standard geno-
types by the primers described below were confirmed by
direct automated DNA sequencing to be the L1 gene DNA
of the expected HPV genotype. This preliminary experi-
ment was to demonstrate that the methodology used in
this study was capable of generating genotype-specific
template suitable for DNA sequencing.
The purified HPV type-16 DNA was used as the routine
positive control and molecular grade pure water instead of
DNA extract was used as negative control for each PCR
run. To avoid cross contamination, three separate rooms
with no air re-circulation were dedicated to nucleic acid
amplification tests. Two of the rooms were each equipped
with a 32" PCR workstation (AirClean Systems, Raleigh,
NC). All pre-amplification procedures were performed in
PCR station I. All post-PCR procedures were carried out in
PCR station II, including preparations for the nested PCR
and sequencing reaction. Gel electrophoresis and DNA
sequencing were performed in the third isolation room.
No post-PCR materials or any items contaminated by
amplicons, or equipment used in the post-PCR roomsBMC Clinical Pathology 2009, 9:3 http://www.biomedcentral.com/1472-6890/9/3
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were allowed to enter the pre-PCR working space. The lab-
oratory is certified by the State of Connecticut Department
of Public Health under the Clinical Laboratory Improve-
ment Amendments of 1988 (CLIA) to perform human
papillomavirus (HPV), Chlamydia trachomatis and Neisse-
ria gonorrhoeae tests by polymerase chain reaction (PCR)
and DNA sequencing, based on methods previously pub-
lished [26-28].
Three thousand two hundred twenty-two (3,222) alcohol-
preserved Cytyc or Surepath liquid-based Pap cytology
specimens submitted by gynecologists in southern Con-
necticut for routine HPV testing were used for this study.
The patients included 2,633 Milford residents representa-
tive of a population in the rural and suburban United
States with a cervical cancer rate less than 6.8 per 100,000
women [29]. In the latter resident group, the HPV positive
rate among the patients below 30 years old was previously
found to be 36.1%, and that for those 30 years and older
was 7.3% [30]. The HPV tests were ordered for the patients
30 years and older (up to 65) as adjunctive screening to
routine Pap cytology and for the patients below age 30
who had a cytology diagnosis of ASCUS or more severe
cytological changes. Publication of the laboratory data
with blinded patient identities was approved by the Mil-
ford Hospital IRB.
For HPV detection and genotyping, the pellet derived
from 1 mL of the ThinPrep (Cytyc) or 0.5 mL of the Sure-
Path cell suspension was washed in reagent grade water,
then in 1 mL buffer consisting of 50 mM Tris-HCl, 1 mM
EDTA, 0.5% Tween 20, pH 8.1. The washed cell pellet was
re-suspended and digested at 45–55°C overnight in 100
μL of 0.1 mg/mL proteinase K (Sigma Chemical Co., St.
Louis, MO) dissolved in the same washing buffer. After
denaturing the proteins in the cell digestate in a metal
block heated to 95°C for 10 min and a final centrifuga-
tion of the digestate at 13,000 rpm for 5 min, the superna-
tant was used for PCR without further purification.
For primary PCR amplification, 1 μL of the crude diges-
tate, 1 μL of 10 μmolar MY09 primer, 1 μL of 10 μmolar
MY11 primer and 2 μL of water were added to a PCR tube
containing 20 μL of LoTemp™ HiFi® DNA polymerase
ready-to-use mix (HiFi DNA Tech, LLC, Trumbull, CT)
which contained all the components needed for low tem-
perature PCR, including dNTPs, Mg++, buffer, HiFi® DNA
polymerases, proprietary dsDNA melting agents and
dNTP preservatives, to reach a final 25 μL reaction vol-
ume. For thermocycling, the temperature steps of a TC-
412 Thermal Cycler (Techne Incorporated, Burlington,
NJ) were programmed for an initial heating at 85°C for 10
min, followed by 30 cycles at 85°C for 30 sec, 40°C for 30
sec, and 65°C for 1 min. The final extension was 65°C for
10 min as previously described [26-28].
For the nested PCR, a "trace" of the MY09/MY11 PCR
products was transferred by a glass rod of about 1.5 mm
in diameter with clean wettable surface to a second PCR
tube containing 25 μL of complete nested PCR reaction
mixture consisting of 20 μL of LoTemp™ HiFi®  DNA
polymerase ready-to-use mix, 1 μL of 10 μmolar GP5+
primer, 1 μL of 10 μmolar GP6+ primer and 3 μL of water,
using the same thermocycling program described above.
Alternatively, the GP5+/GP6+ nested primers were
replaced by the GP6/MY11 heminested PCR primer pair
or the optimized modified equivalent, HiFi HPV nested
PCR primer pair (catalog #3002, HiFi DNA Tech, Trum-
bull, CT) to generate a 190–200 bp nested PCR product
for improved base resolution in direct automated DNA
sequencing.
After completion of the primary and the nested PCR, a 5
μL aliquot of the PCR products was pipetted out from
each tube and mixed with 2 μL loading fluid for electro-
phoresis in a 2% agarose gel containing ethidium bro-
mide. The gel was examined under UV light. Visualization
of a 450 bp PCR product band in the MY09/MY11 lane
and/or a 150 bp (190–200 bp when the GP6/MY11 hem-
inested PCR or the HiFi nested PCR primers were used)
band in the nested PCR lane provided presumptive evi-
dence of an HPV DNA in the sample, pending genotyping
by direct DNA sequencing for final validation.
When the aforementioned nested PCR failed to re-amplify
an MY09/MY11 PCR amplicon to generate an expected
150–200 bp amplicon, a trace of the MY09/MY11 PCR
products was subjected to a long nested PCR using the
heminested GP5/MY09 primers or an equivalent opti-
mized long nested PCR primer pair (catalog #3003) to
generate a 380–395 bp amplicon for DNA sequencing.
This 380–395 bp nested PCR amplicon is referred to as a
"long nest" in this article, to be distinguished from the
aforementioned 190–200 bp nested PCR products (short
nest).
The positive nested PCR products were subjected to direct
automated DNA sequencing without further purification.
Briefly, a trace of the nested PCR products was transferred
from the PCR tube with a calibrated glass rod described
above into a reaction mixture containing 1 μL of GP6
(GP5 for long nest PCR amplicon) or the optimized HiFi
HPV sequencing primer (catalog #6007), 1 μL of BigDye
Terminator (v 1.1/Sequencing Standard Kit, Applied Bio-
systems, Foster City, CA), 3.5 μL 5× buffer, and 14.5 μL of
water in a total volume of 20 μL. This reaction mixture was
subjected to 20 enzymatic primer extension/termination
reaction cycles, according to the protocol supplied by the
manufacturer (Applied Biosystems). The final reaction
mixture was loaded in an automated ABI 3130 four-capil-
lary genetic analyzer for sequence analysis. SequenceBMC Clinical Pathology 2009, 9:3 http://www.biomedcentral.com/1472-6890/9/3
Page 4 of 10
(page number not for citation purposes)
alignments were performed against the standard HPV L1
gene sequences stored in the GenBank database by BLAST
analysis for final validation of the HPV genotyping. An
exclusive "100% identities" match between the query and
subject sequences, returned by the on-line algorithm, was
required for genotyping except for variants not yet
recorded in the GenBank.
To distinguish the overlapping base-calling peaks on a
computer-generated electropherogram which resulted
from co-amplification of non-HPV DNA in the sample,
from those which were caused by co-amplification of
more than one HPV DNA, the agarose gel band contain-
ing the nested PCR amplicon was cut out and crushed in
a 0.5 mL Eppendorf tube containing 10 μL water to elute
the DNA in question. A trace of the eluted DNA was trans-
ferred into another nested PCR tube containing all the
nested PCR components for a second nested PCR. After
the low temperature thermocycling described above, a
trace of the second nested PCR product was subjected to
direct automated DNA sequencing, and its electrophero-
gram was compared with that using the first nested PCR
amplicon as the sequencing template.
One μL of each digestate sample was placed in a separate
PCR tube with a β-globin primer pair for human genomic
DNA amplification as a control of specimen adequacy.
Specimens with no β-globin gene amplification were
excluded as insufficient.
Results
A total of 352 among the 3,222 specimens submitted for
HPV detection and genotyping were found to be positive
for HPV DNA, including 20 positive repeat tests. Since
HPV testing was ordered for patients below age 30 only
when there was a history of abnormal Pap cytology, the
HPV positive rate of the specimens from this group was
about 5 times higher than that in those collected from
patients age 30 or older [30].
Of the 352 specimens tested positive for HPV DNA, 324
(92%) were found to be infected by a single HPV geno-
type and 28 (8.0%) by more than one HPV genotype.
There were 35 single HPV genotypes identified, including
HPV-6, -11, -16, -18, -31, -32, -33, -35, -39, -40, -45, -51,
-52, -53, -54, -56, -58, -59, -61, -62, -66, -67, -68, -69, -70,
-71, -72, -73, -74, -81, -83, -84, -86, -87, and -91, all vali-
dated by a segment of signature sequence within the L1
region flanked by the MY09 and MY11 PCR primers, and
confirmed by the GenBank database. The efficiency of
DNA amplification of the individual HPV genotypes by
the chosen consensus PCR primers varied greatly and
appeared to be type-dependent. While the majority of the
positive nested PCR amplicons of HPV-16, HPV-18, HPV-
31, HPV-33 and HPV-35 were associated with a well
defined 450 bp band in the companion MY09/MY11 pri-
mary PCR gel, most of the other HPV genotypes depended
on a nested PCR for detection (Table 1).
The GP5+/GP6+ nested PCR primers were effective, capa-
ble of generating a 150 bp nested PCR amplicon for most
HPV isolates which had been previously amplified by the
MY09/MY11 primers. In 189 (53.7%) of the specimens, a
clearly defined target PCR product band was visualized in
the nested PCR agarose gel, but not in the companion gel
of the primary PCR amplified with the MY09/MY11 prim-
ers. The MY09/MY11 primary PCR products of 2 isolates
of HPV-39, 1 isolate of HPV-59, 1 isolate of HPV-73 and
1 isolate of HPV-91 could not be amplified by the Gp5+/
GP6+ nested PCR primers. These latter HPV isolates
required a heminested PCR with the GP6/MY11 primers
or the HiFi nested PCR primers (catalog #3002) to gener-
ate a 190–200 bp nested PCR amplicon from the primary
PCR products for direct automated DNA sequencing.
When the GP5+/GP6+ PCR primers were used to generate
a 150 bp nested PCR amplicon for direct automated DNA
sequencing and the GP6 nucleotide as the sequencing
primer, the readily readable sequence for base calling on
the electropherogram was 30 to 50 bases long immedi-
ately downstream of the GP5+ primer site. However, some
variants of HPV-16, HPV-31 and HPV-33 share an identi-
cal 34-base sequence in this region (Table 2). The 190–
200 bp amplicon generated by the GP6/MY11 hemin-
ested or the HiFi HPV nested PCR primers added the
entire GP5+ primer site along with its adjacent upstream
bases to the electropherogram for alignment algorithm.
On this expanded electropherogram, any 34-base strand
inclusive of the entire or part of the GP5+ primer site (Fig-
ure 1) could be used as the signature sequence to distin-
guish these 3 closely related "high risk" HPV genotypes.
The exact location of the signature sequence in this hyper-
variable region may vary from genotype to genotype,
based on the GenBank database. Any 50-base sequence
from this region was found to be sufficient for validation
of all HPV genotypes detected.
One isolate of HPV-39, 1 of HPV-35, 1 of HPV-53 and 2
of HPV-83, which were initially amplified by the MY09/
MY11 PCR primer pair, were not re-amplified either with
the GP5+/GP6+ or with the GP6/MY11 heminested or the
HiFi nested PCR primer pair. But their MY09/MY11
amplicons were successfully amplified with the GP5/
MY09 heminested or the HiFi "long nest" PCR primers
(catalog #3003) to generate a 380–395 bp amplicon for
DNA sequencing. According to information provided by
the vendor (HiFi DNA Tech, LLC), the long nest PCR
primers have been designed for amplification of the seg-
ment flanked by the GP5/MY09 primers.
DNA sequencing of a short segment of the L1 gene for HPV
genotyping was straightforward when a single HPV wasBMC Clinical Pathology 2009, 9:3 http://www.biomedcentral.com/1472-6890/9/3
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present in the specimen. Overlapping and ambiguous base
calling peaks on the computer-generated DNA sequencing
electropherogram were caused by co-amplification of non-
HPV DNAs by the consensus or degenerate PCR primers, or
by co-amplification of more than one HPV genotypes in the
sample. A double nested PCR procedure which re-amplified
the first 190–200 bp nested PCR product excised from the
agarose gel with a second nested PCR easily eliminated the
non-HPV DNA amplicons which had interfered with the
DNA sequencing process. In one case selected for illustra-
tion, this second nested PCR generated a more homogene-
ous template for DNA sequencing, resulting in a 72-base
tracing with distinct base calling peaks (Figure 2) for BLAST
analysis. The results of the sequence alignment algorithm
suggested that this was a putative HPV-87 subtype having a
"100% identities" match in amino acid sequence, but only
90% similarities in nucleotide sequence with the HPV-87
prototype stored in the GenBank database.
Table 1: HPV L1 gene amplification by MY09/MY11 PCR primers followed by positive short or long nested PCR
HPV Type MY09/MY11+ MY09/MY11- Total isolates
Short Long Short_ Long
6 80 1 2 N 2 0
11 10 0 N 1
16 40 0 28 N 68
18 1 6 05 N2 1
31 1 1 04 N1 5
32 30 0 N 3
33 40 1 N 5
35 61 0 N 7
39 41 7 N 1 2
40 20 3 N 5
45 40 5 N 9
51 20 0 N 2
52 90 1 6 N 2 5
53 21 0 N 3
54 50 1 3 N 1 8
56 40 1 1 N 1 5
58 60 3 N 9
59 40 8 N 1 2
61 20 5 N 7
62 20 5 N 7
66 00 9 N 9
67 00 1 N 1
68 00 1 N 1
69 00 2 N 2
70 10 5 N 6
71 00 2 N 2
72 40 2 N 6
73 40 7 N 1 1
74 00 1 N 1
81 30 4 N 7
83 22 1 N 5
84 20 1 N 3
86 00 4 N 4
87 00 1 N 1
91 00 1 N 1
Mixed 7 0 21 N 28
Total 158 5 189 352
MY09/MY11+ = 450 bp amplicon visualized on primary PCR gel.
MY09/MY11- = 450 bp amplicon not visualized on primary PCR gel.
Short = 150 bp or 190–200 bp nested PCR amplicon visualized.
Long = 380–395 bp nested PCR needed due to failure of short PCR.
N = not performed.
Underlined are "High-risk" HPVs targeted by Digene hc2 assay.BMC Clinical Pathology 2009, 9:3 http://www.biomedcentral.com/1472-6890/9/3
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When a sample contained two or more genotypes of HPV
DNA which were co-amplified during the first nested PCR
and resulted in an ambiguous electropherogram with
numerous overlapping base calling peaks, a second nested
PCR could not generate a more homogeneous DNA tem-
plate for DNA sequencing. For these mixed HPV infec-
tions, we relied on using specific HPV-16, -18, -6 and -11
DNA sequencing primers [31] to perform 4 individual
DNA sequencing reactions to rule out the existence of
these Gardasil® vaccine-relevant HPVs [32].
Discussion
The role of persistent infection by HPV as a tumor pro-
moter in uterine cervical cancer induction has been recog-
nized [33-37]. However, the issues of persistence of an
HPV infection, the epidemiology of HPV infection, and
the immunologic responses to an HPV infection are ade-
quately studied only when HPV type-specific or perhaps
even HPV variant-specific methods are available to the
clinical laboratories which perform routine HPV tests for
patient management. Since the FDA does not consider
methods based on probe hybridization to be reliable for
HPV genotyping [18], laboratory-developed HPV assays
must be validated [12,13] by more stringent analyses.
Determination of the DNA base sequence of the L1 gene is
the foundation of genotyping of all papillomaviruses [19].
However, DNA sequencing of the entire L1 gene [38] or
performing multiple reactions to sequence a double-
stranded template of the L1 gene from opposing ends [25]
are beyond the financial feasibility of most clinical labora-
tories. A practical approach is to determine a short signa-
ture sequence in the hypervariable region of the L1 gene,
which is unique for each HPV genotype as identified and
confirmed by the GenBank database [20,22,23]. But, the
cost for sample preparation and purification of the clinical
A typical signature sequence excised from an electropherogram generated by direct automated DNA sequencing, including 23  bases of the GP5+ priming site (underlined) Figure 1
A typical signature sequence excised from an electropherogram generated by direct automated DNA 
sequencing, including 23 bases of the GP5+ priming site (underlined). The template was generated by a pair of HiFi 
HPV nested PCR primers (equivalent to length flanked by GP6/MY11). A sequence of any 34 of these 53 bases confirms that 
this is an HPV-31 L1 gene DNA through BLAST sequence alignment algorithm. Any 50-base sequence in this region can be 
used for accurate genotyping of all known HPVs.
Table 2: HPV-16, -31 and -33 variants with close sequence similarity at the L1 gene GP5+ primer binding site
Highly similar DNA sequence Genotype Locus
5'_acgcagtacaaatatgtcattatgtgctgccata HPV-16 EU779755
5'_acgcagtacaaatatgtcattatgtgctgccata HPV-31 EF140820
5'_acgcagtacaaatatgtcattatgtgctgccata HPV-33 DQ448214
5' tttgttggggtaaccaactatttgttactgttgt HPV-16 EU779755
5' tttgttggggcaatcagttatttgttactgtggt HPV-31 EU779751
5' tttgttggggcaatcaggtatttgttactgtggt HPV-33 EU779744
DNA sequences retrieved from the National Center for Biotechnology Information database. The symbol 
_ and the underlined bases represent the end and the beginning of the GP5+ PCR priming site, 
respectively. A 34-base sequence shared by HPV-16 and certain HPV-31 (EF140820) and HPV-33 (DQ448214) 
strains is located immediately downstream of the GP5+ site. A 1- to 4-base difference is present 
upstream of the GP5+ site between certain variants of HPV-16, HPV-31 (EU779751) and HPV-33 (EU779744).BMC Clinical Pathology 2009, 9:3 http://www.biomedcentral.com/1472-6890/9/3
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materials prior to the DNA sequencing procedure is still
inhibitory for implementation of such approach. The intro-
duction of the low-temperature PCR system with a robust
DNA polymerase, which does not require sample purifica-
tion or DNA extraction, has simplified the process to direct
DNA sequencing procedure, making rigorous validation of
HPV genotyping in a clinical laboratory economically sus-
tainable [26-28,30]. Using this system, the unpurified PCR
products used for nested PCR and for enzymatic primer
extension/termination reactions can be transferred by a
small glass rod to avoid post-amplification micropipetting,
which is the major source of cross contamination in routine
diagnostic operations when a nested PCR is used.
We found that 189 of the 352 HPV isolates (53.7%) need
a nested PCR for detection by agarose gel electrophoresis.
The majority of HPV-16, HPV-18, HPV-31, HPV-33, HPV-
35 and HPV-58 isolates are detected by the MY09/MY11
primary PCR alone (Table 1). But, 28 of the 68 (41.2%)
HPV-16 isolates still depend on a nested PCR for detec-
tion. The HPV-18 DNA appears to be most effectively
amplified since16 of the 21 isolates (76.2%) of HPV-18
were detected by a single MY09/MY11 PCR. Without a
nested PCR, most of the samples containing HPV-39,
HPV-52, HPV-54, HPV-56, HPV-59, HPV-66 and HPV-73
DNAs would have been classified as negative. Other
authors have reported that a similar nested PCR amplifi-
cation may increase the sensitivity of the single MY09/
MY11 PCR by 10-fold [22]. Some even claimed that the
sensitivity of a prototype PGMY09/11 single primer PCR
assay is below that of the HPV hc2 assay although the hc2
assay might have classified some non-target "low-risk"
HPVs as "high-risk" positives due to cross reactivity [39].
The nested PCR procedure described here detects 33.3%
more sequencing-validated "high-risk" HPVs in liquid-
based Pap cytology specimens than the hc2 assay when
parallel tests were conducted on split samples [26], simi-
lar to the findings reported by others [22].
A 30-year old patient (NB) had persistent positive "high-risk" HPV hc2 assays in spite of negative Pap cytology findings 3 years  after a cone biopsy which confirmed a CIN3/2 lesion with HPV-52 DNA isolated from the archived paraffin-embedded tissue Figure 2
A 30-year old patient (NB) had persistent positive "high-risk" HPV hc2 assays in spite of negative Pap cytology 
findings 3 years after a cone biopsy which confirmed a CIN3/2 lesion with HPV-52 DNA isolated from the 
archived paraffin-embedded tissue. The electropherogram of DNA sequencing on a recent liquid-based cytology sample 
shows an ambiguous tracing (upper tracing). However, using a second nested PCR product as the template for sequencing 
reaction, the base-calling peaks (lower tracing) can be deciphered. Alignment of the complementary sequence in reading frame 
spaced as amino acid codons compared to nucleotides 6727–6798 of GenBank Locus AJ400628 is as follows: 5' aat ggt att tgc 
tgg ttt aat caa ttg ttt gtt aca gtt gtg gat acc act aga agt acc aat ttt act att Sample NB. 5' aat ggt att tgc tgg ttt aat cag ttg ttt gta acg 
gtt gtt gat act act cgc agt acc aat ttt act att AJ400628. Although the sequence of sample NB has a mismatch of 7 bases (under-
lined) against those of an HPV-87 prototype, the amino acid sequence, NGICWFNQLFVTVVDTTRSTNFTI, coded by both 
nucleotides is identical in this segment.BMC Clinical Pathology 2009, 9:3 http://www.biomedcentral.com/1472-6890/9/3
Page 8 of 10
(page number not for citation purposes)
Our data have demonstrated that the sensitivity of the
MY09/MY11 amplification of HPV DNA is relatively low.
More than half of the positive cases are only detected in
the nested PCR using GP6/MY11 primers after routine sec-
ond amplification. In this protocol, only when a case was
found to be positive for a 450 bp MY09/MY11 primary
PCR amplification with a concomitant negative 190–200
bp nested GP6/MY11 PCR result, a supplementary long
nested PCR using the GP5/MY09 primers was performed
to amplify the 380–395 bp segment of DNA downstream
of the GP5 primer-binding site. Since the latter long
nested PCR is not routinely performed on all samples, this
procedure may miss some MY09/MY11 PCR negative
cases which can be demonstrated in a GP5/MY09 nested
PCR setting only.
The cohort of 3222 patients used in this study consists of
two age groups and includes 2633 cases previously ana-
lyzed. According to the data reported in the latter study
[30], the prevalence rates of the first 5 most common
"high-risk" HPV genotypes are HPV-16 (22.9% in women
below 30; 14.8% in older women), HPV-52 (6.4% in
women below 30; 10.0% in older women), HPV-18
(6.4% in women below 30; 7.1% in older women); HPV-
31 (2.7% in women below 30; 4.1% in older women; and
HPV-56 (5.5% in women below 30; 2.7% in older
women). Based on our experience, HPV-16 seems to be
more prevalent in women below 30, and HPV-52 is more
frequently detected in women age 30 or older in this sub-
urban US female population who are under the care of
board-certified gynecologists in private practice.
When the consensus or degenerate PCR primers are used
to amplify a minute quantity of HPV DNA of more than
100 genotypes with varying degrees of mismatching in
DNA sequence at the priming sites in an unpurified cervi-
covaginal sample digestate, co-amplification of non-HPV
DNAs derived from the human genome and from other
microbes in the vaginal flora is sometimes unavoidable.
Under these conditions, each primer seeks to anneal to its
most preferred HPV DNA among numerous nucleotides
to initiate the enzymatic primer extension reaction. There-
fore, most of the nested PCR products can be used for
direct automated DNA sequencing reaction without puri-
fication because the competing non-HPV DNAs are
poorly replicated or not replicated, and simply diluted out
in the nested PCR procedure. The L1 genes of the HPV-6,
HPV-16, HPV-18, HPV-31, HPV-33 and HPV-35 appar-
ently provide more preferred templates for the consensus
PCR primers than those of other genotypes since their
nested PCR amplicons usually present themselves as well-
defined bands in the expected position with little con-
comitant high molecular-weight amplicons in the agarose
gel after electrophoresis. However, when the target HPV
DNA at the priming sites is less preferred by the primers
and is amplified with lower efficiencies, the poorly used
primers may bind to other competing non-HPV DNAs,
causing nonspecific co-amplification during PCR thermo-
cycling, which may in turn generate base calling difficul-
ties in DNA sequencing. This kind of sequencing failure
was demonstrated when the DNA of a putative novel sub-
type of HPV-87 was amplified by the first nested PCR in
the presence of competing non-HPV DNAs. Using a sec-
ond nested PCR in which the HPV DNA of the first nested
PCR products was eluted for re-amplification under iden-
tical nested PCR conditions, a homogeneous nested PCR
product was then generated for a successful DNA sequenc-
ing reaction (Figure 2).
The overlapping peaks caused by mixed HPV infections,
in which more than 1 HPV DNA is repeatedly co-ampli-
fied by the same nested PCR primers, cannot be elimi-
nated by using a second nested PCR amplicon for DNA
sequencing. However, since consensus PCR primers do
not amplify DNA from different HPV genotypes with the
same degree of efficiency, it is possible that one single
HPV DNA template is preferentially amplified during its
exponential replication under the nest PCR setting to the
exclusion of other concomitant HPV in mixed HPV infec-
tions. This preferential DNA amplification might have
accounted for the low 8% multiple HPV infections
observed in this series.
A 34-base sequence immediately downstream of the
GP5+ PCR primer site has been proposed as the general
signature sequence to identify all known HPV genotypes
[20]. We have found that a 34-base sequence is too short
for distinguishing some of the closely related HPV geno-
types, in particular for some variants of HPV-16, HPV-31
and HPV-33, which share an identical 34-base DNA
sequence in this region (Table 2). The more reliable signa-
ture sequence for distinguishing the variants of these three
genotypes is located in the region upstream of this seg-
ment (Figure 1), including part of or the entire GP5+
priming site. For validation of the typing of some variants,
a 50-base sequence is needed as unequivocal evidence.
The L1 gene DNA sequences of these 3 genotypes are so
close to each other that in the same pool of samples, HPV-
16 was found to be the most prevalent genotype by one
probe hybridization method and HPV-31 the most preva-
lent by another [16], suggesting that some target DNA of
these two HPV variants may have been interchangeably
labeled as one type or the other by different probe hybrid-
ization methods.
DNA sequencing not only can accurately determine an
HPV genotype. It can also unveil novel HPV subtypes or
variants, as demonstrated in the case selected for illustra-
tion. Sequence alignment algorithm has confirmed that
the GenBank database does not contain an HPV sequenceBMC Clinical Pathology 2009, 9:3 http://www.biomedcentral.com/1472-6890/9/3
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fully matched with the sequence of DNA amplified by the
nested PCR in this case (Figure 2, lower tracing). The clos-
est sequence alignment is a 90% identities match with the
prototype L1 gene of HPV-87 according to the BLAST
analysis, making it marginally qualified as an HPV-87, by
genotyping definition [19]. On careful analysis, this 72-
base DNA sequence encodes an amino acid sequence
NGICWFNQLFVTVVDTTRSTNFTI, which is 100%
matched with the amino acid sequence of the HPV-87
prototype in this region (GenBank Locus AJ400628, HPV-
87 putative L1 protein). As a result, this novel HPV is
accepted as a putative subtype of HPV-87. Association of
HPV-87, a rare HPV genotype, with CIN3 lesions has been
reported by others [40,41]. However, this is not the case
here because HPV-52 was the only HPV DNA recovered
from the paraffin-embedded tissue excised by a cone
biopsy which was performed for a CIN3 lesion with exten-
sion into endocervical glands three years earlier. One
novel HPV-39 variant with a single nucleotide substitute
in this hypervariable segment, resulting in change of an
amino acid codon (leucine to valine), was observed in a
case of persistent HPV infection with a multifocal CIN1
lesion in a 19-year old woman [30]. These findings indi-
cate that DNA sequence variation in this hypervariable
region may, or may not, reflect different amino acid com-
position of the L1 protein in an HPV genotype.
Conclusion
Direct automated DNA sequencing is a reliable means for
validation of HPV genotyping in a routine clinical micro-
biology laboratory. However, the use of consensus prim-
ers for PCR amplification, the identification of the
signature sequence for different genotypes on the electro-
pherogram, and the analysis of the BLAST sequence align-
ment algorithms for genotyping are some of the
challenging issues that the technical staff of the laboratory
must become familiar with.
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